## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

-	-
OMB Number:	3235-0287
Estimated average	burden
hours per response	: 0.5

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).
--	-------------------------------------------------------------------------------------------------------------------------------------

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Woiwode Thomas			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Millendo Therapeutics, Inc.</u> [ TPST ]		tionship of Reporting Person(s) to Issuer (all applicable) Director X 10% Owner		
					Officer (give title		Other (specify
(Last) (First) (Middle) 7000 SHORELINE COURT SUITE 275		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/25/2021		below)		below)
			4. If Amendment, Date of Original Filed (Month/Day/Year)		vidual or Joint/Group	Filing	(Check Applicable
(Street)				Line)			
SOUTH SAN	~ .	94080		X	Form filed by One Reporting Person		
FRANCISCO	CA				Form filed by Mor Person	e than	One Reporting
(City)	(State)	(Zip)					

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(
Common Stock	06/25/2021		A		997,940	A	(1)	997,940	<b>I</b> (2)	By Versant Venture Capital VI, L.P. (2)
Common Stock	06/25/2021		A		1,171,094 <sup>(5)</sup>	A	(1)	1,171,094	<b>I</b> (3)	By Versant Venture Capital IV, L.P. (3)
Common Stock	06/25/2021		A		7,377 <sup>(6)</sup>	A	(1)	7,377	<b>I</b> (4)	By Versant Side Fund IV, L.P. <sup>(4)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

						-									
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Expira		Expiration Da	Expiration Date (Month/Day/Year)		e and int of rities rlying ative ative (Instr. 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

## Explanation of Responses:

1. In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was \$1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc."

2. These shares are held of record held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

3. These shares are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the general partner of VVC IV. The Reporting Person is a managing member of VVI and may be deemed to share voting and dispositive power over the shares held by VVC IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

4. These shares are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the general partner of VSF IV. The Reporting Person is a managing member of VV IV and may be deemed to share voting and dispositive power over the shares held by VSF IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

5. This amount includes 301,161 shares that were acquired upon conversion of 9,352,838 shares of Tempest, which VVC IV agreed to purchase at a purchase price of \$0.85 per share pursuant to a Funding Agreement with Tempest, which was conditioned upon the satisfaction or waiver of the conditions to Closing.

6. This amount includes 1,897 shares that were acquired upon conversion of 58,927 shares of Tempest, which VSF IV agreed to purchase at a purchase price of \$0.85 per share pursuant to a Funding Agreement with Tempest, which was conditioned upon the satisfaction or waiver of the conditions to Closing.

/s/ Pierre Lorenzo, attorney-infact for Thomas Woiwode 06/29/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.